Key points are not available for this paper at this time.
There is a wide diversity in the immune tumor microenvironments in preclinical models and in human HCC, highlighting the need to use multiple syngeneic HCC models to improve the understanding of how to treat HCC through immune modulation.
Zabransky et al. (Tue,) studied this question.